Aliases & Classifications for Cannabis Abuse

Summaries for Cannabis Abuse

Disease Ontology : 12 A substance abuse that involves the recurring use of cannabis despite negative consequences.

MalaCards based summary : Cannabis Abuse, also known as marijuana abuse, is related to cocaine dependence and cannabis dependence. An important gene associated with Cannabis Abuse is CNR1 (Cannabinoid Receptor 1), and among its related pathways/superpathways are Nanog in Mammalian ESC Pluripotency and Ras signaling pathway. The drugs Dopamine and Clozapine have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and lung, and related phenotype is no phenotypic analysis.

Related Diseases for Cannabis Abuse

Graphical network of the top 20 diseases related to Cannabis Abuse:



Diseases related to Cannabis Abuse

Symptoms & Phenotypes for Cannabis Abuse

MGI Mouse Phenotypes related to Cannabis Abuse:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 no phenotypic analysis MP:0003012 8.92 BDNF CHRNA3 CNR1 NGF

Drugs & Therapeutics for Cannabis Abuse

Drugs for Cannabis Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Not Applicable 51-61-6, 62-31-7 681
2
Clozapine Approved Phase 4,Not Applicable 5786-21-0 2818
3
Risperidone Approved, Investigational Phase 4,Not Applicable 106266-06-2 5073
4 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
5 Adrenergic Agents Phase 4,Phase 2,Phase 3
6 GABA Agents Phase 4,Phase 3,Not Applicable
7 Serotonin Agents Phase 4,Phase 2,Not Applicable
8 Serotonin Antagonists Phase 4,Not Applicable
9 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
11 Tranquilizing Agents Phase 4,Phase 3,Not Applicable
12 Dopamine Agents Phase 4,Not Applicable
13 Dopamine Antagonists Phase 4,Not Applicable
14 Antipsychotic Agents Phase 4,Phase 3,Not Applicable
15 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Atomoxetine Hydrochloride Phase 4,Phase 2
17
Serotonin Investigational, Nutraceutical Phase 4,Phase 2,Not Applicable 50-67-9 5202
18
Ethanol Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 64-17-5 702
19
Valproic Acid Approved, Investigational Phase 3 99-66-1 3121
20
Dronabinol Approved, Illicit Phase 2, Phase 3,Phase 1,Early Phase 1 1972-08-3 16078
21
Clonidine Approved Phase 2, Phase 3 4205-90-7 2803
22 Anti-Infective Agents Phase 2, Phase 3,Phase 1,Not Applicable
23 Anti-Infective Agents, Local Phase 2, Phase 3,Phase 1,Not Applicable
24 Lithium carbonate Phase 3 554-13-2
25 Analgesics Phase 2, Phase 3,Phase 1,Early Phase 1
26 Hallucinogens Phase 2, Phase 3,Early Phase 1
27 Analgesics, Non-Narcotic Phase 2, Phase 3,Phase 1,Early Phase 1
28 Hormone Antagonists Phase 2, Phase 3,Early Phase 1
29 Hormones Phase 2, Phase 3,Early Phase 1
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Early Phase 1
31 Peripheral Nervous System Agents Phase 2, Phase 3,Phase 1,Early Phase 1
32 Anticonvulsants Phase 3,Phase 2
33 Antidepressive Agents Phase 3,Phase 2
34 Antimanic Agents Phase 3
35 Autonomic Agents Phase 2, Phase 3,Phase 1
36 Cannabinoid Receptor Agonists Phase 2, Phase 3,Early Phase 1
37 Adrenergic Agonists Phase 2, Phase 3
38 Adrenergic alpha-2 Receptor Agonists Phase 2, Phase 3
39 Adrenergic alpha-Agonists Phase 2, Phase 3
40 Sympatholytics Phase 2, Phase 3
41 Antihypertensive Agents Phase 2, Phase 3
42 Quetiapine Fumarate Phase 3 111974-72-2
43
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
44
Topiramate Approved Phase 2 97240-79-4 5284627
45
Fluoxetine Approved, Vet_approved Phase 2 54910-89-3 3386
46 Respiratory System Agents Phase 2
47 N-monoacetylcystine Phase 2
48 Expectorants Phase 2
49 Antidotes Phase 2
50 Antioxidants Phase 2

Interventional clinical trials:

(show all 34)
# Name Status NCT ID Phase Drugs
1 Clozapine for Cannabis Use in Schizophrenia Completed NCT01639872 Phase 4 Clozapine;Risperidone
2 Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual Completed NCT00498550 Phase 4 Clozapine;Treatment as usual
3 Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE Terminated NCT00687609 Phase 4 Atomoxetine
4 A Comparison of Adolescent Group Therapy and Transitional Family Therapy for Adolescent Alcohol and Drug Abusers Unknown status NCT00484367 Phase 2, Phase 3
5 Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder Completed NCT00194129 Phase 3 Lithium;Divalproex;Placebo
6 Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia Recruiting NCT01598896 Phase 2, Phase 3 Dronabinol;Clonidine;Placebo
7 Quetiapine XR in Schizophrenic Patients Terminated NCT01071135 Phase 3 Quetiapine XR
8 Integration of (iSBIRT) for Teen Drug Use Into a Pediatric Network Withdrawn NCT01454206 Phase 2, Phase 3
9 Clinical Trial of N-acetylcysteine Versus Placebo Efficacy in the Cannabis Withdrawal Unknown status NCT01439828 Phase 2 N-acetylcystein
10 Biobehavioral Effects of Topiramate on Cannabis-Related Outcomes in Adolescents Completed NCT01110434 Phase 2 Topiramate;Placebo
11 The Teen Marijuana Check-Up Completed NCT00350285 Phase 2
12 Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence Completed NCT00149643 Phase 2 Fluoxetine
13 Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder Completed NCT00142961 Phase 2 Atomoxetine
14 Integrated CBT for Cannabis Dependence With Co-occurring Anxiety Disorders Completed NCT01875796 Phase 1
15 Relapse Prevention for Suicidal Dually Diagnosed Youths Completed NCT00589641 Phase 1
16 Dual Diagnosis (Psychosis and Cannabismisuse): Comparison of Specialized Treatment Versus Unspecified Treatment Completed NCT00783185 Phase 1
17 Effects of Sativex(Registered Trademark) and Oral THC on Attention, Affect, Working Memory, Reversal Learning, Physiology and Brain Activation Completed NCT01037608 Phase 1 Sativex(Registered Trademark);THC
18 Medications Development for the Treatment of Cannabis Related Disorders Completed NCT01204723 Phase 1 Placebo Aprepitant;Active Aprepitant
19 Trial of Computerized SBI to Reduce Teen Alcohol Use Withdrawn NCT01784627 Phase 1
20 INCA - Intervention and Neuropsychology in Cannabis Abuse Unknown status NCT00279604 Not Applicable
21 Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis Completed NCT00484302 Not Applicable
22 Effect of Motivational Therapy on Schizophrenia With Cannabis Misuse Completed NCT00798109 Not Applicable
23 Quiting Marijuana Use: Self-report Study of Quitting Straegies and Withdrawal Symptoms Completed NCT01603992
24 Niacin Flushing as Marker of Cannabis Effects on Arachidonic Acid Pathways in Schizophrenia Completed NCT00376233
25 Study Comparing Two Types of Psychotherapy for Treating Depression and Substance Abuse Completed NCT00108407 Not Applicable
26 First Episode Schizophrenia and Cannabis-Related Disorder Study Completed NCT00573287 Not Applicable clozapine;risperidone
27 Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer Completed NCT01647425
28 Dronabinol Interactions With Cognitive Enhancing Drug in Humans Completed NCT00842985 Early Phase 1 drug condition
29 COGNITIVE BEHAVIORAL THERAPY PROGRAM TO FIRST-EPISODE PSYCHOSIS PATIENTS AND CANNABIS ABUSE Recruiting NCT02319746 Not Applicable
30 Treatment for Teens With Alcohol Abuse and Depression Recruiting NCT02227589 Not Applicable
31 Affective Management Training for Cannabis Misuse Recruiting NCT03432013 Not Applicable
32 Electrophysiological Study of the Functioning of Magnocellular Visual Pathway in Regular Cannabis Users Recruiting NCT02864680 Not Applicable
33 Suicide Re Attempts in Young Adults After First Suicide Attempt : Socio-demographic, Clinical and Biological Correlates Recruiting NCT03538197 Not Applicable
34 Alcohol and Tobacco Consumption in Patients With Head and Neck Cancer : Interest of an Addiction Support Withdrawn NCT01652456 Not Applicable

Search NIH Clinical Center for Cannabis Abuse

Genetic Tests for Cannabis Abuse

Anatomical Context for Cannabis Abuse

MalaCards organs/tissues related to Cannabis Abuse:

41
Testes, Brain, Lung, Thyroid

Publications for Cannabis Abuse

Articles related to Cannabis Abuse:

(show top 50) (show all 101)
# Title Authors Year
1
Age Invariance of the Cannabis Abuse Screening Test in a Probabilistic Sample of Cannabis Users. ( 29495016 )
2018
2
Long lasting effects of chronic heavy cannabis abuse. ( 28314070 )
2017
3
The Cannabis Abuse Screening Test and the DSM-5 in the general population: Optimal thresholds and underlying common structure using multiple factor analysis. ( 29124816 )
2017
4
Transverse myelitis associated with heroin and cannabis abuse: a new issue from the past. ( 27003705 )
2016
5
Cannabis Abuse Is Increasing and Associated with Increased Emergency Department Utilization in Gastroenterology Patients. ( 26935430 )
2016
6
Shifting the Paradigm: Adolescent Cannabis Abuse and the Need for Early Intervention. ( 26800275 )
2016
7
Assessing the structure of the CAST (Cannabis Abuse Screening Test) in 13 European countries using multigroup analyses. ( 27981662 )
2016
8
Concomitant cannabis abuse/dependence in patients treated with opioids for non-cancer pain. ( 26246069 )
2015
9
Properties of the Cannabis Abuse Screening Test (CAST) in the general population. ( 26077195 )
2015
10
Sex-dependent vulnerability to cannabis abuse in adolescence. ( 25941498 )
2015
11
Cannabis abuse effects on prepulse inhibition in patients with first episode psychosis in schizophrenia. ( 25716487 )
2015
12
The influence of age and gender on the likelihood of endorsing cannabis abuse/dependence criteria. ( 25481449 )
2015
13
Methamphetamine and cannabis abuse in adolescence: a quasi-experimental study on specific and long-term neurocognitive effects. ( 25636791 )
2015
14
Authors' Response to "Parental Cannabis Abuse and Accidental Intoxication in Children: Prevention by Detecting Neglectful Situations and At-Risk Families". ( 26427950 )
2015
15
Commentary on Kosty et al. (2015): Cannabis abuse from one generation to the next-a heightened vulnerability in women? ( 26094497 )
2015
16
Cannabinoid hyperemesis should be recognised as an effect of chronic cannabis abuse. ( 25120899 )
2014
17
Long-term cannabis abuse and early-onset cannabis use increase the severity of cocaine withdrawal during detoxification and rehospitalization rates due to cocaine dependence. ( 25262527 )
2014
18
Functioning of Cannabis Abuse and Dependence Criteria Across Two Different Countries: The United States and The Netherlands. ( 25363693 )
2014
19
Cannabis abuse and age at onset in schizophrenia patients with large, rare copy number variants. ( 24685822 )
2014
20
Predicting cannabis abuse screening test (CAST) scores: a recursive partitioning analysis using survey data from Czech Republic, Italy, the Netherlands and Sweden. ( 25264894 )
2014
21
Increased CB2 mRNA and anandamide in human blood after cessation of cannabis abuse. ( 24788457 )
2014
22
Parental Cannabis Abuse and Accidental Intoxications in Children: Prevention by Detecting Neglectful Situations and At-Risk Families. ( 25407034 )
2014
23
The association between cannabis abuse and subsequent schizophrenia: a Swedish national co-relative control study. ( 24990397 )
2014
24
Elevated homocysteine level in first-episode schizophrenia patients--the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse. ( 24682777 )
2014
25
Contributions of ethnicity to differential item functioning of cannabis abuse and dependence symptoms. ( 23384380 )
2013
26
Adolescent ischemic stroke associated with anabolic steroid and cannabis abuse. ( 23382306 )
2013
27
Pathways to Psychosis in Cannabis Abuse. ( 23491968 )
2013
28
Psychometric Properties of the Cannabis Abuse Screening Test in Hungarian Samples of Adolescents and Young Adults. ( 24217457 )
2013
29
Additive effects of childhood abuse and cannabis abuse on clinical expressions of bipolar disorders. ( 24028906 )
2013
30
WITHDRAWN: Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. ( 23780682 )
2013
31
Monitoring of chronic Cannabis abuse: an LC-MS/MS method for hair analysis. ( 23305934 )
2013
32
Chronic cannabis abuse, delta-9-tetrahydrocannabinol and thyroid function. ( 22821384 )
2013
33
Cannabis abuse is associated with better emotional memory in schizophrenia: a functional magnetic resonance imaging study. ( 23906663 )
2013
34
Cannabis abuse in adolescence and the risk of psychosis: A brief review of the preclinical evidence. ( 23916409 )
2013
35
A validation of the Cannabis Abuse Screening Test (CAST) using a latent class analysis of the DSM-IV among adolescents. ( 23519957 )
2013
36
Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence. ( 22907121 )
2013
37
Neurological soft signs in patients with psychosis and cannabis abuse: a systematic review and meta-analysis of paradox. ( 22716154 )
2012
38
Validation of the Cannabis Abuse Screening Test in a sample of cannabis inpatients. ( 22472963 )
2012
39
Cannabis abuse and vulnerability to psychosis: targeting preventive services. ( 22239586 )
2012
40
Alcohol and cannabis abuse/dependence symptoms and life satisfaction in young adulthood. ( 21733007 )
2012
41
The validity of DSM-IV cannabis abuse and dependence criteria in adolescents and the value of additional cannabis use indicators. ( 21205060 )
2011
42
Psychometric modeling of cannabis initiation and use and the symptoms of cannabis abuse, dependence and withdrawal in a sample of male and female twins. ( 21507586 )
2011
43
Effects of handedness (left vs right) and cannabis abuse on intermanual coordination and negative symptoms in schizophrenic patients of the paranoid type. ( 21082479 )
2011
44
Bilateral testicular self-castration due to cannabis abuse: a case report. ( 21861879 )
2011
45
Psychometric properties of the Cannabis Abuse Screening Test (CAST) in a French sample of adolescents. ( 20869178 )
2011
46
Developmental pathways to adolescent cannabis abuse and dependence: child maltreatment, emerging personality, and internalizing versus externalizing psychopathology. ( 21534646 )
2011
47
From child maltreatment to adolescent cannabis abuse and dependence: a developmental cascade model. ( 20883588 )
2010
48
Increased cortical inhibition deficits in first-episode schizophrenia with comorbid cannabis abuse. ( 19997844 )
2010
49
Functional MRI evidence for inefficient attentional control in adolescent chronic cannabis abuse. ( 20600341 )
2010
50
Cannabis abuse and severity of psychotic and affective disorders in Israeli psychiatric inpatients. ( 19932824 )
2010

Variations for Cannabis Abuse

Expression for Cannabis Abuse

Search GEO for disease gene expression data for Cannabis Abuse.

Pathways for Cannabis Abuse

GO Terms for Cannabis Abuse

Cellular components related to Cannabis Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 9.43 CHRNA3 CHRNB3 CNR2
2 axon GO:0030424 9.33 BDNF CNR1 NGF
3 acetylcholine-gated channel complex GO:0005892 8.96 CHRNA3 CHRNB3
4 dendrite GO:0030425 8.92 BDNF CHRNA3 CNR2 NGF

Biological processes related to Cannabis Abuse according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 excitatory postsynaptic potential GO:0060079 9.6 CHRNA3 CHRNB3
2 neuron projection morphogenesis GO:0048812 9.59 BDNF NGF
3 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.58 CNR1 CNR2
4 cation transmembrane transport GO:0098655 9.58 CHRNA3 CHRNB3
5 sensory perception of pain GO:0019233 9.57 CNR1 CNR2
6 nervous system process GO:0050877 9.56 CHRNA3 CHRNB3
7 modulation of chemical synaptic transmission GO:0050804 9.55 BDNF NGF
8 neuromuscular synaptic transmission GO:0007274 9.54 CHRNA3 CHRNB3
9 regulation of neuron differentiation GO:0045664 9.52 BDNF NGF
10 synaptic transmission, cholinergic GO:0007271 9.51 CHRNA3 CHRNB3
11 memory GO:0007613 9.5 BDNF CNR1 NGF
12 peripheral nervous system development GO:0007422 9.49 BDNF NGF
13 nerve development GO:0021675 9.48 BDNF NGF
14 locomotion GO:0040011 9.46 BDNF NGF
15 nerve growth factor signaling pathway GO:0038180 9.43 BDNF NGF
16 negative regulation of nitric-oxide synthase activity GO:0051001 9.4 CNR1 CNR2
17 positive regulation of collateral sprouting GO:0048672 9.37 BDNF NGF
18 negative regulation of mast cell activation GO:0033004 9.26 CNR1 CNR2
19 negative regulation of action potential GO:0045759 9.16 CNR1 CNR2
20 cannabinoid signaling pathway GO:0038171 8.96 CNR1 CNR2
21 response to nicotine GO:0035094 8.8 CHRNA3 CHRNB3 CNR1

Molecular functions related to Cannabis Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular ligand-gated ion channel activity GO:0005230 9.37 CHRNA3 CHRNB3
2 ligand-gated ion channel activity GO:0015276 9.32 CHRNA3 CHRNB3
3 acetylcholine binding GO:0042166 9.26 CHRNA3 CHRNB3
4 acetylcholine-gated cation-selective channel activity GO:0022848 9.16 CHRNA3 CHRNB3
5 acetylcholine receptor activity GO:0015464 8.96 CHRNA3 CHRNB3
6 cannabinoid receptor activity GO:0004949 8.62 CNR1 CNR2

Sources for Cannabis Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....